FDA Approves INVOKANA — Janssen Pharmaceuticals, Inc.

Janssen Pharmaceuticals received FDA approval for INVOKANA, a novel SGLT2 inhibitor for the treatment of type 2 diabetes, which is poised to capture significant market share and drive substantial revenue growth for the company.